id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-3632-0008,FDA,FDA-2026-P-3632,Response Letter,Other,Response(s),2026-10-06T04:00:00Z,2026,10,2026-10-06T04:00:00Z,,2026-10-07T00:05:31Z,,0,0,09000064b963a03e
FDA-2026-P-3632-0007,FDA,FDA-2026-P-3632,"Determination PRALIDOXIME CHLORIDE (Autoinjector) (Pralidoxime Chloride) Solution, 600 Milligrams/2 Milliliters (300 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,Determinations,2026-10-06T04:00:00Z,2026,10,2026-10-06T04:00:00Z,,2026-10-06T18:37:10Z,2026-20442,0,0,09000064b962e6a8
FDA-2026-P-3632-0006,FDA,FDA-2026-P-3632,Interim Response,Other,Letter(s),2026-09-17T04:00:00Z,2026,9,2026-09-17T04:00:00Z,,2026-09-17T21:58:55Z,,0,0,09000064b95869bf
FDA-2026-P-3632-0003,FDA,FDA-2026-P-3632,Attachment 1,Supporting & Related Material,Background Material,2026-04-02T04:00:00Z,2026,4,,,2026-04-03T01:19:48Z,,0,0,09000064b924bf7c
FDA-2026-P-3632-0001,FDA,FDA-2026-P-3632,Citizen Petition from Premier Research International LLC,Other,Citizen Petition,2026-04-02T04:00:00Z,2026,4,2026-04-02T04:00:00Z,,2026-04-03T01:19:39Z,,1,0,09000064b924cd42
FDA-2026-P-3632-0004,FDA,FDA-2026-P-3632,Attachment 2,Supporting & Related Material,Background Material,2026-04-02T04:00:00Z,2026,4,,,2026-04-03T01:19:52Z,,0,0,09000064b924bf7d
FDA-2026-P-3632-0002,FDA,FDA-2026-P-3632,"Acknowledgement Letter from FDA DMB to Premier Research International, LLC",Other,Acknowledgement Letter/Receipt,2026-04-02T04:00:00Z,2026,4,2026-04-02T04:00:00Z,,2026-04-03T01:19:44Z,,0,0,09000064b924cd44
FDA-2026-P-3632-0005,FDA,FDA-2026-P-3632,Attachment 3,Supporting & Related Material,Background Material,2026-04-02T04:00:00Z,2026,4,,,2026-07-12T10:05:02Z,,0,0,09000064b924bf7e